Therapeutic benefit of intrathecal injection of marrow stromal cells on XXXX -injured spinal cord.

@entity1603 @entity63 @entity95 @entity2759 @entity432
BACKGROUND: Prophylactic transplantation of marrow stromal cells (MSCs) before @entity2759 has been shown to attenuate neurologic injures. We sought to investigate the therapeutic effect of MSCs on @entity63 -injured spinal cord. METHODS: Marrow stromal cells were expanded in vitro and prelabeled with @entity1603 . @entity2759 was induced in @entity95 by @entity432 for 30 minutes. Four groups were enrolled. About 1 x 10(8) MSCs were intrathecally injected 2 hours (group MSC-2h), 24 hours (group MSC-24h), or 48 hours (group MSC-48h) after @entity2759 , respectively. The control group received intrathecal injection of medium alone. Hind-limb motor function was assessed during a 28-day recovery period with Tarlov criteria, and then histologic examination was performed. RESULTS: Marrow stromal cells still could be found in the spinal cord 4 weeks after transplantation. The capillary density in the ventral gray matter was significantly increased in the three MSC-treated groups (p < 0.01 versus control group, respectively). After a 28-day recovery, marked functional improvement was detected in group MSC-2h (from day 1 to 28, p < 0.05, versus control group, respectively) and group MSC-24h (from day 14 to 28, p < 0.05, versus control group, respectively), but not in group MSC-48h. The number of intact motor neurons was much greater in group MSC-2h (p < 0.05, versus control group). CONCLUSIONS: Intrathecal injection of MSCs enhances angiogenesis in the host spinal cord and improves the motor functional recovery after @entity2759 . The therapeutic time window is critical for the therapeutic effect of MSCs.
